OptimizeRx (OPRX) Stock Price, News & Analysis

Company Overview

OptimizeRx, Inc. is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations. These tools allow pharmaceutical and biotechnology firms to deliver personalized messaging to physicians and care teams, ensuring that relevant formulary and financial support information is accessible at the moment of treatment. In addition, OptimizeRx provides data analytics and reporting capabilities that enable clients to measure the impact of their digital outreach and refine strategies to drive prescription growth and patient outcomes.

Founded in 2003 and headquartered in Cleveland, Ohio, OptimizeRx has formed partnerships with a broad spectrum of EHR vendors and health systems across the United States. The company’s network reaches tens of thousands of healthcare providers, making it one of the largest point-of-care communication platforms in the country. OptimizeRx collaborates closely with payers to integrate eligibility and benefit information, ensuring that savings offers and coverage details are accurate and up to date.

OptimizeRx is led by Chief Executive Officer David Whitlinger, who joined the company in 2019 and has overseen its expansion of digital service offerings and strategic alliances. Under his leadership, the company has focused on enhancing interoperability, scaling its network footprint and delivering advanced analytics to clients. While its primary market remains the U.S., OptimizeRx continues to explore opportunities to extend its digital health network into new regions and therapeutic areas.

Key Stats

• Today's Range: $18.91 to $19.64
• 50-Day Range: $15.49 to $20.51
• 52-Week Range: $3.78 to $20.85
• Volume: 79,850 shs
• Average Volume: 371,162 shs
• Market Capitalization: $362.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.39
• Consensus Rating: Moderate Buy

OptimizeRx Stock Analysis - MarketRank™

OptimizeRx scored higher than 32% of companies evaluated by MarketBeat, and ranked 519th out of 660 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.

Downside Risk

OptimizeRx has a consensus price target of $13.39, representing about 31.6% downside from its current price of $19.58.

Amount of Analyst Coverage

OptimizeRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptimizeRx is -36.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptimizeRx is -36.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OptimizeRx has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.26% of the outstanding shares of OptimizeRx have been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in OptimizeRx has recently decreased by 0.58%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptimizeRx does not currently pay a dividend.

Dividend Growth

OptimizeRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.26% of the outstanding shares of OptimizeRx have been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in OptimizeRx has recently decreased by 0.58%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.00

News Sentiment

OptimizeRx has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 3 articles on an average week.

Search Interest

Only 14 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

11 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OptimizeRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $224,864.00 in company stock.

Percentage Held by Insiders

Only 5.60% of the stock of OptimizeRx is held by insiders.

Percentage Held by Institutions

76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPRX Stock Analysis - Frequently Asked Questions

How have OPRX shares performed this year?

OptimizeRx's stock was trading at $4.86 at the beginning of 2025. Since then, OPRX shares have increased by 302.9% and is now trading at $19.5810.

How were OptimizeRx's earnings last quarter?

OptimizeRx Corp. (NASDAQ:OPRX) issued its earnings results on Monday, May, 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.19. The business had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a positive trailing twelve-month return on equity of 4.50% and a negative net margin of 9.42%.
Read the conference call transcript.

Who are OptimizeRx's major shareholders?

OptimizeRx's top institutional shareholders include Rice Hall James & Associates LLC (2.94%), Calamos Advisors LLC (0.41%), Harbor Capital Advisors Inc. (0.12%) and Brendel Financial Advisors LLC (0.09%). Insiders that own company stock include William J Febbo, James Paul Lang, Stephen L Silvestro, Patrick D Spangler and Marion Odence-Ford.
View institutional ownership trends.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 10/23/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: COMP - SOFTWARE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OPRX
• CIK: 1448431
• Web: www.optimizerx.com
• Phone: (248) 651-6568
• Fax: 248-453-5529
• Employees: 100
• Year Founded: 2006

Price Target and Rating

• Average Price Target for OptimizeRx: $13.39
• High Price Target: $23.00
• Low Price Target: $5.00
• Potential Upside/Downside: -28.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.54
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.66 million
• Net Margins: -9.42%
• Pretax Margin: -8.88%
• Return on Equity: 4.50%
• Return on Assets: 3.12%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 2.57
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: $92.13 million
• Price / Sales: 3.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.35 per share
• Price / Book: 2.96

Miscellaneous

• Outstanding Shares: 18,570,000
• Free Float: 17,525,000
• Market Cap: $349.49 million
• Optionable: Optionable
• Beta: 1.25